Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas

CONCLUSION: The combination of avutometinib and defactinib demonstrates promising in vitro and in vivo anti-tumor activity against primary UCS cell lines and xenografts.PMID:38703673 | DOI:10.1016/j.ygyno.2024.04.010

Source: Gynecologic Oncology - May 4, 2024 Category: Cancer & Oncology Authors: Cem Demirkiran Michelle Greenman Stefania Bellone Blair McNamara Tobias Max Philipp Hartwich Diego Manavella Levent Mutlu Margherita Zipponi Yang Yang-Hartwich Kevin Yang Elena Ratner Peter E Schwartz Silvia Coma Jonathan Pachter Alessandro D Santin Source Type: research